Atypical Antipsychotics in Bipolar Disorder

Atypical (second-generation) antipsychotics are among the most commonly used medications in bipolar disorder, and many people are surprised to be offered one when they have never had psychosis. In bipolar disorder these medications are used for mood: several are FDA-approved to treat manic or mixed episodes, a smaller group is approved for bipolar depression, and some are approved for keeping episodes from coming back. This guide sets out which drug is approved for which phase, what the labels say about side effects and monitoring, and how the newest options fit in.

Why an antipsychotic for a mood disorder?

The word "antipsychotic" describes how these drugs were first used, not everything they do. In bipolar disorder, several of them calm the racing, sleepless, driven state of mania within days to weeks, and some lift bipolar depression. NIMH lists atypical antipsychotics alongside mood stabilizers as core bipolar treatments, and notes that antidepressants are added, if at all, to one of these rather than used alone.

Guidelines reflect this. The CANMAT/ISBD 2018 guidelines list quetiapine, asenapine, aripiprazole, paliperidone, risperidone and cariprazine among the first-line options for acute mania, either alone or added to lithium or divalproex. For bipolar I depression, the same guidelines list quetiapine and lurasidone as first-line options, and a 2023 evidence update moved cariprazine up to first-line. Where one of these fits among all the medications used for bipolar disorder depends on the phase of illness, your history and your other health conditions.

FDA-approved bipolar uses, by phase

The table summarizes the bipolar uses we checked against each current FDA label for this guide. Generic names come first, brand names in parentheses. Some labels include further uses, and approval for one phase does not mean a drug helps in the others.

Two patterns stand out. First, only lumateperone is approved for bipolar II depression; the rest of the depression approvals are for bipolar I. Second, pediatric approvals are narrower than adult ones, and the olanzapine label notes that adolescents gain more weight and have more lipid changes, which "may lead clinicians to consider prescribing other drugs first in adolescents." For how these options are used specifically in the depressive phase, see treating bipolar depression.

Metabolic monitoring: weight, glucose and lipids

Every atypical antipsychotic label we checked carries a "Metabolic Changes" warning covering high blood sugar or diabetes, abnormal lipids and weight gain. How much risk each drug carries differs a lot. In a 2020 network meta-analysis of 100 trials (in schizophrenia, the population where most head-to-head data exist), olanzapine and clozapine had the least favorable metabolic profiles and aripiprazole, brexpiprazole, cariprazine, lurasidone and ziprasidone the most favorable.

In 2004 the American Diabetes Association and the American Psychiatric Association, with endocrine and obesity groups, published a consensus statement on monitoring people who take these medications. In practice, monitoring starts before the first dose. NICE CG185 lists the checks to do before starting an antipsychotic in bipolar disorder: weight or BMI, pulse, blood pressure, fasting glucose or HbA1c, and a lipid profile, with an ECG when the product information calls for one or there are heart risk factors. The repeat schedule is set by your prescriber; our guide to lab monitoring for psychiatric medications covers it in detail.

If the scale is already moving, read bipolar medications and weight gain for the bipolar-specific angle and weight gain on psychiatric medication for options a prescriber can discuss.

Akathisia, tardive dyskinesia and other side effects

Akathisia: restlessness you can feel

Akathisia is an inner restlessness, an urge to keep moving, pacing, shifting in your seat, or being unable to stay still. It is listed among the most common side effects in the lurasidone label, and the cariprazine label tells prescribers to watch for movement side effects and akathisia for several weeks after starting and after each dose increase, because they can appear late. Akathisia can be mistaken for anxiety or for a mood episode getting worse, so name it if you notice it. It is often manageable once it is recognized.

Tardive dyskinesia: movements to report early

Tardive dyskinesia (TD) is involuntary, repetitive movement, often of the mouth, tongue, face or fingers, that can develop with longer use. The labels for cariprazine, lurasidone and lumateperone, among others, carry a TD warning and advise considering stopping the drug if signs appear. Catching it early matters, so many prescribers check for it during visits. Tell your prescriber about any new lip smacking, tongue movements or finger movements, even if they seem minor.

Other label warnings

• Sleepiness, dizziness and, with some drugs, low blood pressure on standing.
• Antipsychotics that are approved for depression (for example quetiapine, lurasidone and the olanzapine/fluoxetine combination, as well as aripiprazole) carry the antidepressant-class boxed warning about suicidal thoughts in young people.
• All antipsychotics carry a boxed warning about increased mortality in older adults with dementia-related psychosis.

Newer agents, including Bysanti

The newest bipolar approvals have been extensions of familiar drugs. Cariprazine gained a pediatric indication for mania (age 10 and older) in December 2025, and lumateperone remains the only label covering bipolar II depression. In February 2026 the FDA approved milsaperidone (Bysanti) for acute manic or mixed episodes of bipolar I in adults and for schizophrenia.

Bysanti is a new molecule with a familiar mechanism rather than a new kind of treatment. Our page on newer psychiatric medications explains what that means and what is still unknown about recent approvals, so we will not repeat it here. As with any new medication, long-term experience is limited compared with drugs used for decades.

Clozapine: what changed in 2025

Clozapine has no FDA-approved bipolar indication, though it is sometimes discussed when other treatments have not worked. One thing that changed: the FDA removed the clozapine REMS program effective June 13, 2025, so pharmacies and prescribers no longer have to enroll in or report to that program. The blood-count requirement did not go away. The FDA still says absolute neutrophil count (ANC) should be monitored before and during treatment as the label directs, and the severe neutropenia boxed warning remains.

Questions to bring to your prescriber

• Which phase is this medication meant to treat for me: mania, depression or prevention?
• How will we check my weight, blood sugar and lipids, and what would we do if they change?
• Which side effects should I report right away, and which tend to fade?
• How would we stop or switch it safely if needed? (Stopping suddenly can bring back symptoms or trigger a mood episode.)
• Does my genetic testing or other medication change how this drug is dosed? For many antipsychotics it does not; see pharmacogenomic testing in bipolar disorder.

At Willow & Stone

At Willow & Stone, Dr. Stacey Forbes, a board-certified psychiatric-mental health nurse practitioner (PMHNP-BC), reviews medication options at your evaluation, including whether an atypical antipsychotic makes sense and how it would be monitored; labs are ordered as needed. Visits are in Arlington, Texas or by telehealth for people located in Texas, New Mexico, Florida, Alaska, Arizona, Colorado and Washington. Read more about bipolar disorder treatment at Willow & Stone, start with our complete bipolar disorder guide, or book a consultation.

Common Questions

Sources & Further Reading

• DailyMed: Vraylar (cariprazine) prescribing information (12/2025)
• DailyMed: Latuda (lurasidone) prescribing information
• DailyMed: Caplyta (lumateperone) prescribing information (6/2025)
• DailyMed: Seroquel (quetiapine) prescribing information
• FDA Drug Safety Communication: FDA removes REMS program for clozapine (Aug 2025)
• UTHealth Houston Psychiatry: FDA approval of Bysanti (milsaperidone), Feb 2026
• Keramatian, Chithra & Yatham: The CANMAT and ISBD guidelines, summary and 2023 update of evidence (Focus, 2023)
• NICE CG185: Bipolar disorder: assessment and management (last updated 2 Sept 2025)
• Pillinger et al.: Metabolic effects of 18 antipsychotics, network meta-analysis (Lancet Psychiatry, 2020)

This article is general education, not a diagnosis or advice for your situation. Do not start, stop, or change a medication without talking to the clinician who prescribes it; stopping a mood stabilizer suddenly can trigger relapse.